Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2003, Pages 100-106

  Justesen, Ulrik S ^a   Klitgaard, Niels A ^b   Brosen, Kim ^a   Pedersen, Court ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amprenavir; Antiretroviral therapy; Combination therapy; Delavirdine; Pharmacokinetic interaction; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG SCREENING; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CARBAMATES; DELAVIRDINE; DRUG INTERACTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 0037238536     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01734.x     Document Type: Article

References (24)

1. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126: 946-954.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337: 725-733.
3. Agenerase Product Monograph. Glaxo Wellcome, 1999.
4. Noble S, Goa KL. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 2000;60: 1383-1410.
5. Rescriptor, Product Information. Pharmacia & Upjohn, 1999.
6. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87: 803-807.
7. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001;40: 207-226.
8. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13: 2061-2068.
9. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39: 1704-1710.
10. El-Hajj L, Peytavin G, Bani-Sadr F, Salomon J, Mathez D, de Truchis P. Pharmacodynamics of the ritonavir/amprenavir combination in salvage regimen. AIDS 2000;14 (Suppl 4): P286.
11. von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001;41: 85-91.
12. Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18: 252-259.
13. Wintergerst U, Engelhorn C, Kurowski M, Hoffmann F, Notheis G, Belohradsky BH. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS 2000;14: 1866-1868.
14. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 1999;43: 1686-1692.
15. St Clair MH, Millard J, Rooney J et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996;29: 53-56.
16. Tran JQ, Petersen C, Garret M, Schultz-Smith M, Lillibridge JH, Kerr BM. Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers. 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000: P266 [Abstract/poster].
17. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45: 30-37.
18. Table for Grading Severity of Adult Adverse Experiences. List: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1992.
19. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001;29: 754-760.
20. Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998;287: 381-388.
21. Haubrich R, Thompson M, Schooley R et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS 1999;13: 2411-2420.
22. 3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr 1999;21: 281-292.
23. Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998;12: 1333-1340.
24. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001;15: 1009-1018.